EUCTR2015-000801-38-SE进行中（未招募）1 期
A two-arm, randomised, assessor-blind, parallel group study to evaluate the effect of fluticasone/formoterol breath actuated inhaler (BAI) and Relvar Ellipta DPI on ventilation heterogeneity in subjects with partially controlled or uncontrolled asthma. - KFL3502
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Participants to be included in the study are those who meet all of the following criteria:
- •Inclusion criteria (for participants on Seretide Accuhaler 250/50 µg at screening):
- •1. Male and female participants =18 years old.
- •2. Female participants less than one year post-menopausal must have a negative urine
- •pregnancy test recorded at the screening visit prior to the first dose of study
- •medication, be non-lactating, and willing to use adequate and highly effective
- •methods of contraception throughout the study. A highly effective method of birth
- •control is defined as those which result in a low failure rate (i.e., less than
- •1% per year) when used consistently and correctly such as sterilisation,
- •implants, injectables, combined oral contraceptives, some IUDs (Intrauterine
- •Device, hormonal), true sexual abstinence, where this is in line with the
- •preferred and usual lifestyle of the participant, or vasectomised partner.
- •Note: Periodic abstinence (calendar, ovulation, symptothermal, post-ovulation
- •methods), declaration of abstinence for duration of study, and withdrawal are not
- •acceptable methods of contraception).
- •3. Documented clinical history of asthma for = 6 months prior to screening visit.
- •4. Using Seretide Accuhaler at a stable dose of 250/50 µg BID at screening for = 8
- •5. Uncontrolled asthma as defined by Asthma Control Questionnaire (ACQ-6) score =1.0.
- •6. R5-R20 = 0.10 kPa/L/s as measured on impulse oscillometry during the screening
- •7. Historical evidence (within past 24 months) of eosinophilic airways disease,
- •evidenced by sputum eosinophil count = 3% and/or FeNO = 35 ppb.
- •8. Good compliance with current asthma medication(s) in the Investigators opinion.
- •9. Willing and able to substitute pre-study prescribed inhaled asthma medication for
- •the entire duration of the study.
- •10. Willing and able to attend all study visits.
- •11. Written informed consent obtained.
- •Inclusion criteria (for participants on equivalent /higher dose or other ICS-LABAs or higher dose of Seretide at screening):
- •1. Male and females participants =18 years old.
- •2. Female participants less than one year post-menopausal must have a negative urine
- •pregnancy test recorded at the screening visit prior to the first dose of study
- •medication, be non-lactating, and willing to use adequate and highly effective
- •methods of contraception throughout the study. A highly effective method of birth
- •control is defined as those which result in a low failure rate (i.e., less than
- •1% per year) when used consistently and correctly such as sterilisation,
- •implants, injectables, combined oral contraceptives, some IUDs (Intrauterine
- •Device, hormonal), true sexual abstinence where this is in line with the
- •preferred and usual lifestyle of the participant, or vasectomised partner. Note:
- •Periodic abstinence (calendar, ovulation, symptothermal, post-ovulation methods),
- •declaration of abstinence for duration of study, and withdrawal are not
- •acceptable methods of contraception).
- •3. Documented clinical history of asthma for = 6 months prior to screening visit.
- •4. R5-R20 = 0.07 kPa/L/s as measured on impulse oscillometry during the screening
- •5. Historical evidence (within past 24 months) of eosinophilic airways disease,
- •evidenced by sputum eosinophil count = 3% and/or FeNO = 35 ppb.
- •6. Good compliance with current asthma me
排除标准
- •Participants to be excluded from the study are those who meet any of the following criteria:
- •1. Any severe chronic respiratory disease other than asthma.
- •2. Participant has a smoking history = 10 pack years” (i.e., at least 1 pack of 20
- •cigarettes /day for 10 years or 10 packs/day for 1 year, etc.).
- •3. Current smoking history within 12 months prior to the Screening Visit.
- •4. Near fatal or life-threatening (including intubation) asthma within the past year.
- •5. Known history of systemic (injectable or oral) corticosteroid medication within 1
- •month of Visit 1.
- •6. Evidence of a clinically unstable disease as determined by medical history or
- •physical examination that, in the investigator’s opinion, precludes entry into
- •the study. ‘Clinically unstable’ is defined as any disease that, in the opinion
- •of the Investigator, would put the participant at risk through study participation,
- •or which would affect the outcome of the study.
- •7. In the investigator’s opinion a clinically significant upper or lower respiratory
- •infection within 4 weeks prior to Visit 1.
- •8. Current evidence or known history of alcohol and/or substance abuse within 12
- •months prior to the Screening Visit.
- •9. Participant has taken ß-blocking agents, tricyclic antidepressants, monoamine oxidase
- •inhibitors, astemizole, quinidine type antiarrhythmics, or potent CYP 3A4
- •inhibitors such as ketoconazole within 1 week prior to Screening Visit.
- •10. Current use of bronchodilators / anti-inflammatory agents other than those
- •specified in the protocol.
- •11. Known or suspected sensitivity to study drug or excipients.
- •12. Participation in a clinical drug study within 30 days of the screening visit.
- •13. Current participation in a clinical study
- •Exclusion Criteria for subset of participants undergoing OE-MRI and HD-CT
- •1. Contraindication for MRI scanning (as assessed by local MRI safety
- •questionnaire), which includes but is not limited to: presence of non-MRI
- •compatible artificial heart valves, hydrocephalus shunts, intracranial aneurysm
- •clips, joint replacements or metal implants, pacemakers or other cardiac rhythm
- •management devices, claustrophobia, history of metal in the eye, presence of
- •shrapnel from a war injury, callipers or braces, dentures, dental plates or
- •hearing aids that include metal and cannot be removed, history of epilepsy or
- •black-outs, ear implants, piercings that cannot be removed, intrauterine
- •contraceptive device or coil.
- •2. Inability to stay in the supine position for the duration of the scanning
- •3. Obesity (body weight >140 kg).
- •Randomisation Criteria required following Run-in
- •1. R5-R20 = 0.10 kPa/L/s
- •2. ACQ-6 score =1.0
研究者
相似试验
进行中（未招募）
1 期
A study to compare the effects of fluticasone / formoterol BAI against Relvar® Ellipta® dry powder inhaler (DPI) on asthmaAsthma BronchialeMedDRA version: 19.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 19.1Level: LLTClassification code 10003555Term: Asthma bronchialSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 19.1Level: LLTClassification code 10068462Term: Eosinophilic asthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-000801-38-SKMundipharma Research Limited90
已完成
2 期
To evaluate efficacy, safety and tolerability of two dose strengths of tacrolimus lipid suspension for injection rectally administered in adult patients with ulcerative colitisCTRI/2015/10/006252Intas Pharmaceuticals Ltd60
已完成
3 期
Clinical Study to Evaluate theImmunogenicity and Safety of Influvac® in adults.CTRI/2018/02/012222Abbott India Limited480
进行中（未招募）
1 期
MENOPUR and REKOVELLE in Women UnderGoing an assisted reproductive technology cycleInfertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycleCTIS2022-500308-23-00Ferring Pharmaceuticals A/S151
进行中（未招募）
1 期
A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the efficacy and safety of FE 999049 with follitropin alfa (GONAL-F) in controlled ovarian stimulation in women undergoing an assisted reproductive technology programmeMedDRA version: 16.1Level: PTClassification code 10021926Term: InfertilitySystem Organ Class: 10038604 - Reproductive system and breast disordersInfertilityEUCTR2013-001669-17-PLFerring Pharmaceuticals A/S1,350